Trial

NCT00833768

A Randomised, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphataemic Chronic Kidney Disease Patients Not on Dialysis
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Genzyme, a Sanofi Company
Collaborators
Condition
Chronic Kidney Disease
Intervention
Sevelamer carbonate
Why stopped
After an extensive review,the ASPIRE in CKD study was terminated because it was not possible to complete the study in an appropriate time frame.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-03-24